Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
We are the first company to remove HIV genomes from animals and generate functional cures for HIV.
Excision products require one-time gene edit to remove the viral genome permanently
“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
GLOBE NEWSWIRE
September 2022
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
GLOBE NEWSWIRE
September 2022
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
